Evaluating open access publication and research impact in gynecologic oncology.


Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
ISSN: 1525-1438
Titre abrégé: Int J Gynecol Cancer
Pays: England
ID NLM: 9111626

Informations de publication

Date de publication:
03 07 2023
Historique:
medline: 5 7 2023
pubmed: 24 5 2023
entrez: 23 5 2023
Statut: epublish

Résumé

To evaluate whether a citation advantage exists for open access (OA) publications in gynecologic oncology. A cross-sectional study of research and review articles published in the Overall, 18 515 articles were included, of which 2398 (13.0%) articles were published OA. The rate of OA has increased since 2007. During 2018-2022, the average proportion of articles published OA was 34.0% (range 28.5%-41.4%). OA articles had higher CPY (median (IQR), 3.0 (1.5-5.3) vs 1.3 (0.6-2.7), p<0.001). There was a strong positive correlation between OA proportion and impact factor; OA articles have a higher CPY, with a strong positive correlation between OA proportion and impact factor. OA publishing has increased since 2007, but articles written by authors in low/middle-income countries are under-represented among OA publications.

Identifiants

pubmed: 37220951
pii: ijgc-2023-004460
doi: 10.1136/ijgc-2023-004460
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1112-1117

Informations de copyright

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Gabriel Levin (G)

Lady Davis Institute for Medical Research, Montreal, Quebec, Canada levin.gaby@gmail.com.
The Department of Gynecologic Oncology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Jerusalem, Israel.

Ross Harrison (R)

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, Oregon, USA.

Jonathan Ledermann (J)

University College, UCL Cancer Institute, London, England, UK.

Raanan Meyer (R)

Department of Obstetrics and Gynecology, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars-Sinai Medical Center, Los Angeles, California, USA.

Robert L Coleman (RL)

Sarah Cannon Research Institute (SCRI), HCA Healthcare, Nashville, Tennessee, USA.

Pedro T Ramirez (PT)

Department of Obstetrics and Gynecology, Houston Methodist Hospital, Houston, Texas, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH